Business Context and Reporting Period
This Form 8-K reports on the results of a special meeting of stockholders held by Seastar Medical Holding Corp on September 6, 2023. The filing details the approval of four corporate governance and capital structure proposals.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results.
Material Changes and Voting Results
Stockholders approved the following four proposals:
- Proposal 1 (Reverse Stock Split): Approved an amendment to the Charter to effect a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-100, to be determined by the Board within one year.
- Votes For: 11,039,200
- Votes Against: 583,111
- Proposal 2 (Authorized Shares Increase): Approved increasing the authorized number of common shares from 100,000,000 to 500,000,000.
- Votes For: 11,005,353
- Votes Against: 622,458
- Proposal 3 (Nasdaq Compliance): Approved potential issuance of shares pursuant to the conversion of Notes to comply with Nasdaq Listing Rule 5635(d).
- Votes For: 11,090,484
- Votes Against: 536,455
- Proposal 4 (Equity Plan Increase): Approved increasing the authorized shares under the 2022 Omnibus Equity Incentive Plan to 1,850,000 shares.
- Votes For: 11,027,234
- Votes Against: 600,312
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the context of the approved proposals. The reverse stock split and share authorization increases are typically undertaken to maintain compliance with exchange listing standards or to facilitate future capital raising.
Investor Verification Checklist
- Verify the specific reverse stock split ratio selected by the Board of Directors, as the filing only authorized a range of 1-for-10 to 1-for-100.
- Confirm the timing of the reverse stock split implementation, which may occur at any time within one year of the meeting.
- Review the terms of the "Notes" referenced in Proposal 3 to understand the potential dilution from conversions.
- Monitor future filings for the actual execution of the increased authorized share count and equity plan adjustments.